Lexaria Bioscience Announces 2026 R&D Program

Kelowna, British Columbia — March 4, 2026 — Leads & Copy — Lexaria Bioscience Corp. (Nasdaq: LEXX) has announced the commencement of its 2026 research and development program. The program is designed to broaden pharmaceutical, intellectual property, and business development opportunities through new and improved formulations.

The company is releasing information on three new studies from the 2026 R&D Program, which are representative of the company’s primary areas of focus during the first three quarters of the calendar year. The company notes that these studies do not necessarily encompass the entire 2026 R&D Program.

“Our 2026 R&D Program might be the most focused on practical results that the Company has ever conducted,” stated Richard Christopher, CEO of Lexaria. “These studies are specifically concentrated on increasing the likelihood of pharma industry partnerships and the creation of new intellectual property,” continued Mr. Christopher. “Some of this work must intentionally remain obscure at this time since, if successful, it could likely lead to expanded new IP and patent development.”

One human study and two animal studies are currently in progress.

Human Study GLP-1-H26-7 design is nearing completion. The company expects it to be a 5-week parallel group study consisting of 3 different arms with primary goals of establishing safety and tolerability, as well as pharmacokinetic evaluation. The study will compare salcaprozate sodium-inclusive DehydraTECH-semaglutide tablet and capsule compositions to Wegovy semaglutide tablets under fasted pre-dose conditions.

Generally, this study will evaluate differences between DehydraTECH capsules optimized for intestinal absorption and DehydraTECH tablets experimentally optimized for stomach absorption. It will also evaluate the performance of a SNAC-enabled DehydraTECH-semaglutide formulation that was not previously included in Lexaria’s Phase I Human Study conducted in Australia in 2025.

Study GLP-1-H26-7 will also expand upon the findings of Human Pilot Study #1, which delivered PK and safety results with an earlier iteration of SNAC-inclusive DehydraTECH-semaglutide capsules, but was limited to a single day of dosing. Study GLP-1-H26-7 will target steady-state PK results and will be more robust than Human Pilot Study #1, with roughly 30 subjects expected to be enrolled in each of the study arms concentrating on the tablet comparisons, and 15 subjects in the capsule study arm. Lexaria intends to begin recruitment in this study as early as April. A final study report should be expected in Q4, 2026.

Lexaria is progressing rapidly with design for two animal studies with two objectives: to establish scientific evidence supporting new concepts, procedures and formulations intended to facilitate the development of new IP through the development and filing of patent applications; and second, to test wide varieties of conditions and formulations to narrow down choices prior to potential future corroborating human study work.

Animal Study GLP-1-A26-1 is expected to be a large, single-dose study with between 8-11 different arms. Blood samples are expected to be drawn over an 8-24-hour post-dose period to quantify the PK performance of the active ingredients. The study is expected to test various SNAC-inclusive DehydraTECH-semaglutide formulations with prospective formulation performance enhancements from earlier glucagon-like peptide-1 related work; and in separate arms, test various DehydraTECH-cannabidiol formulations where similar enhancements may be beneficial for Lexaria’s cannabidiol therapeutic program pursuits.

Brain samples will also be taken. A primary goal of this study will be to discover whether new and different formulation enhancements contemplated by Lexaria might enhance PK performance of either of these drug classes. Animal Study GLP-1-A26-1 is anticipated to begin by Q2, 2026 with a final study report expected near the end of Q3, 2026.

Animal Study GLP-1-A26-2 is expected to be a large, single-dose study with between 14-18 different arms. This study will focus on the delivery of DehydraTECH enhanced retatrutide and amycretin, both GLP-1 drugs that Lexaria has never studied before. Some of the study arms will compare the PK performance of test articles placed endoscopically in the intestine versus being swallowed thus targeting the stomach, in order to compare and contrast formulation functionality and performance in these distinct drug delivery dosing regions gastrointenstinally. Blood samples are expected to be drawn over a 24-hour post-dose period to quantify the PK performance of the active ingredients.

Animal Study GLP-1-A26-2 is also anticipated to begin by Q2, 2026 with a final study report expected near the end of Q3, 2026.

Each of the above noted studies will be conducted by independent third-party service providers and individually announced with additional details once they are ready to proceed. Additional R&D work, not yet disclosed, may be completed during 2026.

Lexaria Bioscience Corp. operates a licensed in-house research laboratory and holds an intellectual property portfolio with 60 patents granted and additional patents pending worldwide. DehydraTECH™ is Lexaria’s patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery.

Source: Lexaria Bioscience Corp.